Literature DB >> 10718823

Association of thyrotrophin receptor antibodies with the clinical features of Graves' ophthalmopathy.

M N Gerding1, J W van der Meer, M Broenink, O Bakker, W M Wiersinga, M F Prummel.   

Abstract

OBJECTIVE: Graves' ophthalmopathy (GO) and Graves' hyperthyroidism are closely associated diseases and thought to be caused by the same autoimmune process. An obvious explanation for this would be the presence of autoantibodies reacting with an autoantigen present in the orbit and the thyroid gland. The TSH-Receptor (TSH-R) antibodies are a likely candidate, because they cause Graves' hyperthyroidism and the TSH-R appears to be present also in orbital tissues. If TSH-R antibodies are responsible for the ophthalmopathy one would expect their titres to correlate with clinical characteristics of the eye disease. The aim of the present study is to see whether TSH-R antibodies are related to the activity and severity of the thyroid-associated ophthalmopathy. DESIGN AND PATIENTS: TSH-R antibody levels were measured as TBII (TRAK assay), and TSI (cAMP response of a TSH-R transfected cell line) in serum of 63 patients with untreated moderately severe GO, accompanying Graves' thyroid disease; all patients had been euthyroid for > 2 months.
RESULTS: TBII and TSI titres were strongly related to each other. TBII or TSI titres did not correlate with thyroidal or orbital disease duration, nor with TPO antibody levels. In contrast, we found a striking and highly significant correlation between the Clinical Activity Score (CAS) of the eye disease, and both TBII (r = 0.54; P < 0.0001) and TSI (r = 0.50; P < 0.0001). In addition, a weaker but significant relation was found between proptosis (in mm) and TBII (r = 0.36; P = 0.004) and TSI (r = 0.49; P = 0.0001). No correlation was found with eye muscle motility.
CONCLUSION: TSH-R antibody levels correlate directly with clinical features of Graves' ophthalmopathy. The results support the hypothesis of a pathogenetic role of TSH-R antibodies and the TSH-R in the orbit of Graves' ophthalmopathy patients.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10718823     DOI: 10.1046/j.1365-2265.2000.00959.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  64 in total

Review 1.  [Endocrine orbit disorders. Pathogenesis, clinical presentation and examination, stage-dependent therapy].

Authors:  A Eckstein; J Esser
Journal:  Ophthalmologe       Date:  2003-10       Impact factor: 1.059

2.  Graves' ophthalmopathy: search for shared autoantigen(s) continues.

Authors:  L Bartalena
Journal:  J Endocrinol Invest       Date:  2005-05       Impact factor: 4.256

3.  Euthyroid Graves' ophthalmopathy with negative autoantibodies.

Authors:  Mehtap Cakir
Journal:  J Natl Med Assoc       Date:  2005-11       Impact factor: 1.798

Review 4.  Graves orbitopathy: a perspective.

Authors:  Petros Perros; Gerasimos E Krassas
Journal:  Nat Rev Endocrinol       Date:  2009-06       Impact factor: 43.330

5.  Mechanism of action of a nanomolar potent, allosteric antagonist of the thyroid-stimulating hormone receptor.

Authors:  Chris J van Koppen; Marcel E de Gooyer; Willem-Jan Karstens; Ralf Plate; Paolo G M Conti; Tanja A E van Achterberg; Monique G A van Amstel; Jolanda H G M Brands; Jesse Wat; Rob J W Berg; J Robert D Lane; Andre M M Miltenburg; C Marco Timmers
Journal:  Br J Pharmacol       Date:  2012-04       Impact factor: 8.739

Review 6.  Graves' hyperthyroidism of recent onset and Graves' orbitopathy: to ablate or not to ablate the thyroid?

Authors:  L Bartalena; C Marcocci; A Lai; M L Tanda
Journal:  J Endocrinol Invest       Date:  2008-06       Impact factor: 4.256

Review 7.  Pathogenesis of graves ophthalmopathy: implications for prediction, prevention, and treatment.

Authors:  James A Garrity; Rebecca S Bahn
Journal:  Am J Ophthalmol       Date:  2006-07       Impact factor: 5.258

8.  Autoantibody against aldehyde dehydrogenase 2 could be a biomarker to monitor progression of Graves' orbitopathy.

Authors:  Kai-Chun Cheng; Yu-Jen Wu; Kai-Hung Cheng; Kai-Yuan Cheng; Kuo-Jen Chen; Wen-Chuan Wu; Po-Yen Lee; Cheng-Hsien Chang
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2018-02-03       Impact factor: 3.117

9.  A stimulatory thyrotropin receptor antibody (M22) and thyrotropin increase interleukin-6 expression and secretion in Graves' orbital preadipocyte fibroblasts.

Authors:  Seema Kumar; Reagan Schiefer; Michael J Coenen; Rebecca S Bahn
Journal:  Thyroid       Date:  2010-01       Impact factor: 6.568

Review 10.  [Role of TSH receptor autoantibodies for the diagnosis of Graves' disease and for the prediction of the course of hyperthyroidism and ophthalmopathy. Recommendations of the Thyroid Section of the German Society of Endocrinology].

Authors:  Anja Eckstein; Klaus Mann; George J Kahaly; Martin Grussendorf; Christoph Reiners; Joachim Feldkamp; Beate Quadbeck; Andreas Bockisch; Matthias Schott
Journal:  Med Klin (Munich)       Date:  2009-05-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.